Gan & Lee

Company snapshot

Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Gan & Lee. Not investment advice.

• What is Gan & Lee?

  Gan & Lee is a pharma organization headquartered in CN. Primary therapeutic focus areas include Type 2 Diabetes Mellitus (T2DM). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPT

• Is Gan & Lee publicly traded?

  Gan & Lee appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Gan & Lee develop or market?

  We link 1 drug profile(s) where Gan & Lee is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gan-lee-pharmaceuticals-europe-gmbh#company-drugs.

• What are the latest developments for Gan & Lee?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Gan & Lee focus on?

  Gan & Lee focuses on Type 2 Diabetes Mellitus (T2DM) based on our analysis of their pipeline programs and drug development activities.